Reflexion on a good strategy of use of oxaliplatine with 5-fluorouracil and its derivatives in patients with advanced colorectal cancer;Eléments de réflexion sur une bonne stratégie d'utilisation de l'oxaliplatine en association au 5-fluoro-uracile et à ses dérivés chez les patients ayant un cancer colorectal métastatique

Bulletin du Cancer

Volumn 93, Issue SPEC. ISS., 2006, Pages

  Tournigand, Christophe ^a   De Gramont, Aimery ^a  

^a HÔPITAL SAINT ANTOINE   (France)

Author keywords

5 fluorouracil; Colorectal cancer; EGF; Irinotecan; Oxaliplatin; VEGF

Indexed keywords

CAPECITABINE; EPIDERMAL GROWTH FACTOR RECEPTOR; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; VASCULOTROPIN; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; DRUG DERIVATIVE; FOLFOX PROTOCOL; IFL PROTOCOL; PLATINUM COMPLEX;

CANCER GROWTH; CANCER SURVIVAL; COLORECTAL CANCER; HUMAN; REVIEW; TREATMENT RESPONSE; ARTICLE; CLINICAL TRIAL; COLORECTAL TUMOR;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CLINICAL TRIALS; COLORECTAL NEOPLASMS; FLUOROURACIL; HUMANS; LEUCOVORIN; ORGANOPLATINUM COMPOUNDS;

EID: 33644858853     PISSN: 00074551     EISSN: 17696917     Source Type: Journal    
DOI: None     Document Type: Review

References (13)

1. Levi F, Perpoint B, Garufi C, et al. Oxaliplatin activity against metastatic colorectal cancer. A phase II study of 5-day continuous venous infusion at circadian rhythm modulated rate. Eur J Cancer 1993; 29A: 1280-4.
2. Levi F, Misset JL, Brienza S, et al. A chronopharmacologic phase II clinical trial with 5-fluorouracil, folinic acid, and oxaliplatin using an ambulatory multichannel programmable pump. High antitumor effectiveness against metastatic colorectal cancer. Cancer 1992; 69: 893-900.
3. Garufi C, Brienza S, Pugliese P, et al. Overcoming resistance to chronomodulated 5-fluorouracil and folinic acid by the addition of chronomodulated oxaliplatin in advanced colorectal cancer patients. Anticancer Drugs 2000; 11: 495-501.
4. Andre T, Louvet C, Raymond E, Tournigand C, de Gramont A. Bi-monthly high-dose leucovorin, 5-fluorouracil infusion and oxaliplatin (Folfox3) for metastatic colorectal cancer resistant to the same leucovorin and 5-fluorouracil regimen. Ann Oncol 1998; 9: 1251-3.
5. de Gramont A, Figer A, Seymour M, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000; 18: 2938-47.
6. Goldberg RM, Sargent DJ, Morton RF, et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2004; 22: 23-30.
7. Tournigand C, Andre T, Achille E, et al. Folfiri followed by Folfox6 or the reverse sequence in advanced colorectal cancer: a randomized Gercor study. J Clin Oncol 2004; 22: 229-37.
8. Maindrault-Goebel F, Tournigand C, Andre T, et al. Oxaliplatin reintroduction in patients previously treated with leucovorin, fluorouracil and oxaliplatin for metastatic colorectal cancer. Ann Oncol 2004; 15: 1210-4.
9. Sorbye H, Glimelius B, Berglund A, et al. Multicenter phase II study of Nordic fluorouracil and folinic acid bolus schedule combined with oxaliplatin as first-line treatment of metastatic colorectal cancer. J Clin Oncol 2004; 22: 31-8.
10. Comella P, Massidda B, Filippelli G, et al. Oxaliplatin plus high-dose folinic acid and 5-fluorouracil i.v. bolus (Oxafafu) versus irinotecan plus high-dose folinic acid and 5-fluorouracil i.v. bolus (Irifafu) in patients with metastatic colorectal carcinoma: a Southern Italy Cooperative Oncology Group phase III trial. Ann Oncol 2005; 16: 878-86.
11. Grothey A, Goetz MP. Oxaliplatin plus oral fluoropyrimidines in colorectal cancer. Clin Colorectal Cancer 2004; 4(Suppl 1): S37-S42.
12. Scheithauer W, Kornek GV, Raderer M, et al. Randomized multicenter phase II trial of two different schedules of capecitabine plus oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2003; 21: 1307-12.
13. Ducreux M, Adenis A, Bennouna J, et al. Phase III, randomized, open-labeled study of capecitabine plus oxaliplatin (Xelox) vs. infusional 5-FU/LV plus oxaliplatin (Folfox6) first-line treatment in patients with metastatic colorectal cancer: findings from an interim safety analysis. Am Soc Clin Oncol 2005; 270s.